Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
02.01. | EC approves Rybrevant with Lazcluze for advanced lung cancer | ||
02.01. | UK regulator warns against buying weight-loss medicines without prescription | ||
17.12.24 | MindMed begins phase 3 study of MM120 for anxiety disorder | ||
17.12.24 | German cancer centre treats first patient with Elekta Evo | ||
16.12.24 | CSL receives positive opinion for garadacimab in hereditary angioedema | ||
16.12.24 | Beckley Psytech announces positive results for ELE-101 in depression trial | ||
12.12.24 | Bayer begins SOS1 inhibitor study treating advanced KRAS-mutated tumours | ||
12.12.24 | Leriglitazone meets primary endpoint in pivotal cALD trial | ||
11.12.24 | iOnctura achieves new clinical milestones in uveal melanoma therapy | ||
11.12.24 | Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy | ||
10.12.24 | Cellenkos presents promising phase 1b data for CK0804 in myelofibrosis | ||
10.12.24 | CatalYm shows potential of visugromab for treating cachexia | ||
09.12.24 | Imfinzi receives NICE recommendation for lung cancer treatment | ||
09.12.24 | Poolbeg Pharma presents positive results for POLB 001 | ||
05.12.24 | Teva's Ajovy shows positive results in preventing pediatric migraines | ||
05.12.24 | NICE endorses Neuraxpharm's ublituximab for treating MS | ||
04.12.24 | Antag Therapeutics secures €80 million in weight loss therapy financing | ||
04.12.24 | Everest therapy shows promise in nephropathy trial | ||
03.12.24 | KIMMTRAK recommended for funding by NICE for uveal melanoma patients | ||
03.12.24 | Orbit Discovery and Evergreen Theragnostics expand research collaboration | ||
02.12.24 | OGT launches enhanced genetic profiling panel for CLL | ||
02.12.24 | Pharma giants vie for oral GLP-1R approval | ||
28.11.24 | New injection offers hope for asthma and COPD attacks | ||
28.11.24 | Scientists join forces to speed up vaccine development with new technology | ||
21.11.24 | Cytomos raises $5m to scale up cell analysis technology production |